After binding to the neurokinin-1 (NK-1) receptor, substance P (SP) induces tumor cell proliferation,
angiogenesis, and the migration of tumor cells for invasion and metastasis. After binding to NK-1 receptors, NK-1
receptor antagonists inhibit tumor cell proliferation, angiogenesis and the migration of tumor cells. These antagonists are
broad-spectrum antitumor drugs. In addition, in the host they display beneficial effects: anxiolytic, antiemetic,
neuroprotector, nephroprotector, hepatoprotector, antiinflammatory and analgesic. In combination therapy with classic
cytostatics, NK-1 receptor antagonists have synergic effects and minimize the side-effects of these classic drugs. Thus,
NK-1 receptor antagonists could offer a new and promising generation of anticancer drugs.